Flu remains a major killer because of imperfect vaccines and widespread resistance to existing antivirals-problems particularly acute during a pandemic. New findings at the bedside and at the bench could lead to improvements on both fronts. Grace Chen and Kanta Subbarao discuss the implications of research identifying human antibodies than can neutralize a range of viral subtypes. The findings may help lead to a 'universal' vaccine against these diverse and rapidly evolving viruses. Estanislao Nistal-Villán and Adolfo García-Sastre examine two recent studies that reveal the crystal structure of a promising viral drug target, the unique endonuclease domain of the viral polymerase. The findings open the door to the rational design of new influenza virus inhibitors.
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The influenza virus is constantly changing; immunity to one season's strains does not translate into immunity in subsequent years. As a consequence, the vaccine is reformulated each year. However, several recent studies [1] [2] [3] [4] [5] provide hope that one day a 'universal' influenza vaccine might be developed-one that protects not only against strains circulating in one season but against all strains of influenza.
These studies examined neutralizing antibodies, which block the infectivity of the virus, derived from people previously vaccinated or infected with influenza virus. The research pinpoints a handful of neutralizing antibodies that, surprisingly, are directed against a broad range of influenza strains. These observations from the bedside are provoking basic research into how to develop a vaccine to induce such antibodies and harness them so they effectively protect against a range of strains. Ultimately, a new vaccine strategy may emerge 1, 4, 6 .
Vaccines are the cornerstone of prevention. The principle underlying licensed influenza virus vaccines is the induction of an immune response to two proteins: hemagglutinin, the protein responsible for attachment to sialic acid, the receptor on host cells, and fusion of the viral membrane to the endosome during viral entry; and neuraminidase, the protein that cleaves sialic acid from the virion and cell membranes, releasing progeny virions. These two proteins are the main targets of protective immunity.
There are 16 hemagglutinin and nine neuraminidase subtypes among influenza A viruses, and the 16 hemagglutinin-encoding genes fall into two phylogenetic groups (I and II) 7 . Influenza viruses have succeeded as pathogens because of their ability to escape neutralization by antibodies elicited during previous infection or vaccination. This escape occurs annually by point mutations around the conserved receptor binding pocket of the hemagglutinin (antigenic drift) or, much more rarely, by the introduction of a new hemagglutinin subtype to which the population lacks immunity, resulting in a pandemic (antigenic shift). Annual reformulations of the vaccine are needed to keep pace with antigenic drift in the hemagglutinin, and a completely new vaccine is needed in the event of antigenic shift. Despite the annual influenza vaccine campaigns, influenza accounts for up to 200,000 hospitalizations and 36,000 excess deaths annually in the US 8,9 and 3-5 million cases of severe illness and 250,000-500,000 deaths worldwide 10 .
During influenza infection and after vaccination, neutralizing antibodies typically develop against epitopes on the globular head of the hemagglutinin, a protein that looks a bit like a lollipop, with a stem and a head (Fig. 1) . Neutralizing antibodies are generally specific for antigenically related viruses and do not cross-react with other hemagglutinin subtypes, although T cell responses do cross-react across subtypes 11, 12 .
H1N1 'swine' flu is testing the weak spots in our vaccine and drug defense.
found in HCV-associated lymphomas and antibodies associated with autoimmunity 1 . The selective V H variant usage in antibodies against HIV, HCV and influenza reflect unusual properties of the epitopes; the basis and the consequences of the use of this germ line by viruses of various families will be of interest to immunologists and virologists. Would a vaccine designed to elicit crossreactive antibodies to the influenza hemagglutinin increase the risk of autoimmunity?
As Wang et al. 6 suggest, it may also be possible to rationally design an antiviral drug to mimic this neutralizing antibody to block membrane fusion 4 . tified using combinatorial antibody libraries, which reflect the entire immunologic repertoire of an individual, generated from IgM + memory B cells or from bone marrow RNA. One can increase the probability of finding antibodies of interest by screening large libraries.
These findings provide clear evidence that the human immune system can recognize and produce a neutralizing antibody response to a conserved epitope on the hemagglutinin that is shared across several influenza subtypes.
Most of the universal vaccine design approaches currently being pursued focus on generating cross-protective cellular immunity; most such vaccines provoke a response against conserved viral proteins such as the ion channel M2 or the nucleoprotein. But whereas cellular immune responses are crucial for viral clearance, neutralizing antibodies directed at the hemagglutinin can prevent infection with influenza viruses. Therefore, a universal hemagglutinin-based vaccine could be combined with an M2-or nucleoprotein-based vaccine to provide heterosubtypic protection based on both antibody and cellular immune mechanisms.
Further research will be needed to determine how the conserved hemagglutinin epitope can be engineered into a vaccine. A number of vaccine platforms that present the epitope, including virus-like particles, peptide vaccines or vectored vaccines, can be explored, and their success will be measured by the ability of the vaccine to elicit antibodies that resemble the mAbs in breadth of cross-reactivity.
Evaluation of such vaccines should include studies to determine whether high titers of such antibodies will drive the evolution of the hemagglutinin to escape neutralization, as is common with antibodies directed at the immunodominant sites on the globular head of the hemagglutinin. Structurebased explanations for the lack of binding of these newly identified mAbs to group II hemagglutinins have been proposed 1, 4 . Identification of a similar conserved epitope for the group II hemagglutinins would be necessary to protect against the entire range of hemagglutinin subtypes.
These findings raise research questions that also go beyond influenza. For instance, most of the cross-reactive neutralizing antibodies directed against the influenza viruses contained a particular antibody heavy chain sequence, the immunoglobulin V H 1-69 segment. Preferential use of the V H 1-69 germ line is reported for antibodies against hepatitis C virus (HCV) and HIV and has been
The recent studies identified antibodies that broadly neutralize hemagglutinins of various subtypes. Gioia et al. 2 examined antibodies from individuals immunized with inactivated seasonal influenza virus vaccines and observed neutralizing antibodies and enhanced T cell reactivity against H5N1 'bird flu' viruses. Three independent studies scanned combinatorial antibody libraries in which immunoglobulin light and heavy chains were amplified by PCR from survivors of H5N1 infection 3 or from recipients of seasonal influenza vaccine 5 or a pooled nonimmune human antibody phage display library 4 ; these studies identified human monoclonal antibodies (mAbs) that neutralized hemagglutinins from group I.
Structural studies with two of the mAbs established that binding to the hemagglutinin was mediated exclusively by the immunoglobulin heavy chain 1, 4 without involvement of the light chain, and that the mAbs bound a conserved epitope in the stem region of the hemagglutinin containing the fusion peptide (Fig. 1) . The fusion peptide is a hydrophobic portion of the hemagglutinin that is exposed when the hemagglutinin undergoes a conformational change at low pH in the endosome; the fusion peptide inserts into the endosomal membrane and pulls the endosomal and virion membranes together, causing them to fuse. This portion of the hemagglutinin is broadly conserved across several hemagglutinin subtypes from group I. On the basis of where this region mapped, and on in vitro findings of fusion inhibition, the authors proposed a specific mechanism for how the antibodies neutralized the viruses 1, 4 .
It seems the mAbs lock the fusion peptide in place, preventing the structural reorganization that is required for membrane fusion 2 . The mAbs were also able to prevent infection with several influenza subtypes in mice.
The human mAbs recognize an epitope in a region that was previously identified with a mouse mAb that neutralized H1, H2 and H5 hemagglutinins 13, 14 . Why weren't such cross-reactive neutralizing human antibodies identified earlier? There are two possible explanations. First, the dominant antibody response to the influenza hemagglutinin is strain specific; most of the antibodies are directed at epitopes on the globular head of the hemagglutinin, and cross-reactive antibodies directed at the stem of the hemagglutinin are rare. Second, these rare cross-reactive antibodies were identified with new technology that makes it possible to identify antibodies that cannot be found easily by other means. The mAbs were iden-B e t w e e n B e d s i d e a n d B e n c h 4 and Figure 1 of Ekiert et al. 1 . The heavy chain of the mAbs binds to a conserved epitope in the stem of the hemagglutinin.
